Lv4
458 积分 2024-09-01 加入
A high-throughput selection system for fast-acting covalent protein drugs
1个月前
已完结
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity
1个月前
已完结
Concurrent L1 retrotransposition events promote reciprocal translocations in human tumorigenesis
1个月前
已完结
Targeting Modulated Vascular Smooth Muscle Cells in Atherosclerosis via FAP-Directed Immunotherapy
1个月前
已完结
A high-throughput selection system for fast-acting covalent protein drugs
1个月前
已完结
Mitochondrial metabolism and signaling direct dendritic cell function in antitumor immunity
1个月前
已完结
Transcriptomic Heterogeneity of EGFR -Mutant Non–Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer
1个月前
已关闭
Transcriptomic Heterogeneity of EGFR -Mutant Non–Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer
1个月前
已关闭
Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias
1个月前
已完结
Respiratory viral infections prime accelerated lung cancer growth
1个月前
已完结
Hnrnpu mutations Are Haploinsufficient and Alter the Transcriptome of MYC-Driven Lymphomas
1个月前
已采纳
Cerebrospinal Fluid IL-6 Plus IL-10 As Effective Diagnostic Biomarkers for Secondary Central Nervous System Lymphoma
1个月前
已采纳
Implications of the Chronic Stress Pathway in Acute Myeloid Leukemia
1个月前
已采纳
Mecapegfilgrastim for Preventing Chemotherapy-Induced Neutropenia in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Open-Label, Randomized Controlled Trial
1个月前
已驳回
Myeloid Sarcoma or Extramedullary Acute Myeloid Leukemia: Experience in Managing Single-Centre Patients Cohort
1个月前
已采纳
Clinical characteristics and prognostic factors in myeloid blast-Phase chronic myeloid leukemia
1个月前
已采纳
FLT3/ITD-driven noncanonical STAT1 S727 phosphorylation upregulates CD276, mediating CD8positive- T cell exhaustion and immune evasion in AML
1个月前
已采纳
A first-in-class oral clinical candidate targeting MLLT1 and 3 degradation for the treatment of advanced AML and ALL including menin inhibitor resistant / refractory disease
1个月前
已驳回
Factor v inhibits factor x activation by the tissue factor-factor VIIa complex
1个月前
已采纳
A prospective, multicenter, randomized, controlled clinical trial comparing polatuzumab vedotin, zanubrutinib, lenalidomide, and rituximab (Pola-ZR2) versus zanubrutinib, lenalidomide, and rituximab (ZR2) in the treatment of previously untreated, elderly patients with diffuse large B-cell lymphoma (NCT06522555)
1个月前
已采纳
皖公网安备34019202002308
